PATENT CLAIM ANALYSIS

Application Number: 15927426
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2019-02
Patent Classification: ["514", "278000"]

Abstract:
The present invention provides MDM2 inhibitor compounds of Formula I, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.

Claim (Index 44):
A method of treating nausea in a subject in need thereof, the method comprising administering to the subject an effective amount of the pharmaceutical composition of  claim 43 .

Metadata:
- Claim Count in Document: 2.0
- Percentile: 90.0
- Lexical Diversity: 1.34286
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15008342', '14316586', '13153345', '14347628', '14301087']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7709256088907848
- 35 USC 102 Novelty (BERT): 0.5578270120364566
- Combined Prediction Score: 0.749615749205352
- Mean Citation Score: 386.30228
- Max Citation Score: 464.92166
- Similarity Product: 278.9130471154499

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 0

Dataset: test